Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis: A Multi-cohort, Multi-center Clinical Trial (ALTER-G-001)

NCT05262335 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05262335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis: A Multi-cohort, Multi-center Clinical Trial (ALTER-G-001)
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
December 1, 2024
Enrollment
116 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal tumors